SITES MEDICAL CELEBRATES 350,000 OSTEOSYNC® TI IMPLANTATIONS WORLDWIDE
3 min read Premium comments
milestoneSITES MedicalOsteoSync® Ti implants350,000Greg Stalcupimplantationsporous titaniumorthopedic implants
Columbia City, IN — September 10, 2026 — SITES Medical, a leading developer of advanced orthopedic implant technologies and manufacturing processes, today announced a major milestone: more than 350,000 OsteoSync® Ti implants have now been implanted worldwide.
The milestone marks more than a decade of clinical use for OsteoSync Ti porous titanium technology, with the first US OsteoSync Ti implantation occurring in 2014. Since then, the material has been adopted by 15 orthopedic OEM partners and incorporated into implants used across a remarkably broad range of applications.
“Reaching 350,000 implantations is an extraordinary milestone for SITES Medical and a testament to the OEM partners, surgeons, and patients who have placed their trust in OsteoSync Ti,” said Greg Stalcup, Founder and CEO, SITES Medical. “What makes this achievement particularly meaningful is the breadth of applications and the number of OEM partners who have incorporated OsteoSync into their product portfolios. Since that first US implantation in 2014, OsteoSync has become a proven technology platform spanning virtually every major segment of orthopedics.”
Over A Decade of OsteoSync Ti
Over the past 12 years, its use has expanded well beyond its initial applications. Today, OsteoSync Ti technology has been incorporated into products serving:
Large Joint Reconstruction
Spine
Upper Extremities
Lower Extremities
Sports Medicine
Veterinary Medicine
Soft Tissue Applications
The diversity of these applications reflects the flexibility of the OsteoSync Ti platform and its ability to support different implant geometries, loading environments, clinical requirements and cost targets.
Technology That OEMs Can Build On
OsteoSync Ti is a porous, commercially pure titanium technology platform designed to meet the needs of orthopedic OEMs now and into the future.
Key attributes include:
High initial stability through a high coefficient of friction and tighter than traditional dimensional tolerances to support stable fixation during the early period following implantation.
Advanced porous architecture featuring macro, micro and nano-scale features to support biological fixation and bone integration.
Design flexibility allows OEMs to integrate the technology into a broad range of implant geometries.
High utility technology platform with the ability to attach to various materials including dissimilar metals to support applications across multiple orthopedic markets.
Efficient manufacturing methods to meet cost and scalability requirements.
Importantly, OsteoSync Ti is the trademark established by SITES Medical. Our orthopedic OEM partners often market OsteoSync Ti products under their respective brands.
350,000 Implants. 15 OEM Partners. More Than a Decade of Utility.
The 350,000-implant milestone represents a significant validation of SITES Medical’s vision to provide orthopedic companies with differentiated technologies that can be integrated into innovative products and brought to market efficiently.
“350,000 implantations is a number worth celebrating, but what it really represents is 350,000 opportunities to improve a patient’s life,” said Greg. “We are incredibly proud of the role OsteoSync Ti has played in the success of our OEM partners and the confidence surgeons have placed in the implants incorporating our technology.”
Looking Ahead
“As we look ahead, our focus remains on helping our partners develop the next generation of orthopedic solutions. The experience we’ve gained over more than a decade, and across 350,000 implantations, provides a strong foundation for continued innovation.”
Orthopedic surgery continues to evolve toward cementless fixation, outpatient procedures, and technologies that can improve both clinical and economic outcomes.
SITES Medical is continuing to develop technology platforms to help orthopedic OEMs respond to these changing demands and the list of OEM partners is expected to grow.
About SITES Medical
SITES Medical partners with orthopedic OEMs to design, develop, and deliver next-generation surgical solutions that align with the clinical, economic, and operational demands of modern healthcare. Our integrated platforms, spanning innovative technologies, rapid development, and agile manufacturing, enable faster market entry, reduced risk, and more capital-efficient growth.
SITES Medical’s technology portfolio includes OsteoSync® Ti, a porous titanium platform designed for orthopedic implant applications, along with additional technologies focused on advancing implant performance and healthcare economics.
For more information, visit www.sitesmedical.com.
Media Contact
Greg Stalcup
Founder and CEO
SITES Medical
gstalcup@sitesmedical.com
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
SITES Medical's OsteoSync® Ti achieved 350,000 implantations globally, demonstrating significant market penetration since 2014. This milestone, supported by 15 OEM partners, highlights a successful strategy of providing a versatile technology platform integrated across diverse orthopedic segments. The company's focus on efficient manufacturing and addressing evolving market demands like cementless fixation positions it for continued growth and partner expansion.
- The broad adoption by 15 OEM partners across major orthopedic segments validates SITES Medical's platform strategy and market utility.
- The technology's adaptability to various applications and focus on cost-efficiency supports market trends towards cementless fixation and outpatient procedures.
PhD Lens: Clinical and outcomes impact
OsteoSync® Ti, a porous, commercially pure titanium technology, has achieved 350,000 implantations worldwide over a decade, demonstrating robust clinical adoption. Its advanced architecture, featuring macro, micro, and nano-scale porosity, promotes both initial mechanical stability and long-term biological fixation. The material's versatility allows integration into diverse orthopedic applications, from large joints to soft tissue.
- The technology provides high initial stability through a high coefficient of friction and tight dimensional tolerances, crucial for early post-implantation fixation.
- Its advanced porous architecture supports biological fixation and bone integration, essential for long-term implant success across various loading environments.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.